Pfizer China Congressional Delegate Seeks MRCT Approval Linkage
This article was originally published in PharmAsia News
Executive Summary
In a new proposal submitted for consideration to China’s ongoing Congressional legislative sessions, a lone delegate from multinational drug makers has aggressively advocated legalizing approving new drugs using data obtained from multiregional clinical trials in which China takes part.